SiSaf says acne treatment promising in clinical trials
SiSaf, a Belfast-based biotech firm, has said a clinical test of an acne treatment that uses its technology has shown promising results.
The firm has developed a technique that uses nanoparticles to deliver medication deeper into the skin.
The company said the study showed a 95% reduction in facial acne during a 30-day treatment.
It used patients with moderate to severe acne and was carried out between July and September.
Dr Suzanne Saffie-Siebert, the chief executive of SiSaf, said she believes that treatment could have the potential to "absolutely revolutionise the lives of people who are suffering with acne".
SiSaf has developed its technology at its laboratories in Belfast with the support of InvestNI.
The company is now embarking on a fundraising round with the aim of moving to the manufacturing stage.
SiSaf's chairman John Hartnett said he believes it can attract "large scale private equity capital investment in the coming months".
He pointed to a global market for acne treatment that is estimated to be worth more than £2bn a year.